Arcturus Therapeutics stock analysis
Want to see ARCT full AI Analyst Report?
Arcturus Therapeutics (ARCT) Stock Price & Analysis
ARCT Stock Chart & Stats
- Day’s Range
- $8.12 - $8.68
- 52-Week Range
- $5.50 - $17.96
- Previous Close
- $8.44
- Volume
- N/A
- Average Volume (3M)
- 688.59K
- Market Cap
- $240.96M
- Enterprise Value
- $226.39M
- Total Cash (Recent Filing)
- $184.82M
- Total Debt (Recent Filing)
- $21.86M
- Price to Earnings (P/E)
- ―
- Beta
- 2.26
- Next Earnings
- Mar 11, 2027 (Est.)
- EPS Estimate
- -0.82
- Last Dividend Ex-Date
- Jan 08, 2013
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Improving MRNA Delivery Platform
The reported potency improvement could enable lower or less frequent dosing and expand the diseases addressable with mRNA medicines. If translated clinically, stronger delivery performance may reinforce Arcturus’s technology differentiation and support multiple future programs.
Clinical Pipeline Advancement
Positive ARCT-810 biomarker results, alongside planned ARCT-2601 Phase II dosing, provide evidence of progress across the rare-disease pipeline. Advancing multiple programs can diversify clinical catalysts and improve the company’s ability to convert platform capabilities into therapies.
Extended Funding Runway
A cash runway through 2028 gives Arcturus time to reach several clinical and regulatory milestones without an immediately indicated financing need. This supports continued investment in the pipeline and provides flexibility while programs generate data and partnership opportunities.
Bears Say
Persistent Cash-burning Losses
Negative operating and free cash flow show that the current business is not self-funding. Continued clinical investment therefore consumes capital, and prolonged losses could eventually reduce financial flexibility or require additional funding before products generate recurring revenue.
Sharp Revenue Contraction
The steep revenue decline highlights the volatility of Arcturus’s collaboration and grant-driven revenue model. Lower recognized revenue reduces near-term operating support and underscores that future financial performance depends heavily on new milestones, partnerships, or successful commercialization.
Uncertain ARCT-032 Phase III Timing
Uncertainty around the Phase III start delays clarity on the development path for a key cystic-fibrosis program. Additional data analysis and FDA engagement are still required, which could extend timelines, postpone potential partnership contributions, and defer any future product revenue.
Arcturus Therapeutics News
Arcturus Therapeutics: Buy Rating Reaffirmed as ARCT-032 and ARCT-2601 Catalysts Support Unchanged $20 Price Target
In a report released today, Thomas Shrader from BTIG maintained a Buy rating on Arcturus Therapeutics, with a price target of $20.00. Thomas Shrader’s rating is based on several factors,
Analyst Maintains Hold on Arcturus as Early LUNAR 2.0 Promise Balances ARCT-810 Uncertainties; $9 Price Target Reaffirmed
Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Arcturus Therapeutics. The associated price target remains the same with $9.00. Andrew Fein has given his Hold rating
Arcturus Therapeutics announces interim OTC deficiency Phase 2 results
The company states: “Arcturus Therapeutics (ARCT) announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase deficiency and introduced LUNAR 2.0, the Company’s next-generation mRNA delivery platform, and additional
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
What is Arcturus Therapeutics’s market cap?
When is Arcturus Therapeutics’s upcoming earnings report date?
How were Arcturus Therapeutics’s earnings last quarter?
Is Arcturus Therapeutics overvalued?
Does Arcturus Therapeutics pay dividends?
What is Arcturus Therapeutics’s EPS estimate?
How many shares outstanding does Arcturus Therapeutics have?
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Arcturus Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Arcturus Therapeutics Stock Smart Score
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Joseph E. Payne
- Employees
- 109
- Website
- arcturusrx.com
- Address
- 10628 Science Center Drive, San Diego, CA, 92121, US
Arcturus Therapeutics (ARCT) Earnings & Revenues
ARCT Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, with encouraging ARCT-810 clinical data, a reported 38-fold LUNAR 2.0 potency improvement, progress in the ARCT-032 and ARCT-2601 programs, expanding pipeline capabilities and a cash runway through year-end 2028. The main negatives were the significant year-to-date revenue decline, higher year-to-date net loss, reduced cash balance and uncertainty around the timing of a potential ARCT-032 Phase III start.
View all ARCT earnings summariesARCT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |











